First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.

By P. Trzonkowski, M. Bieniaszewska, Jolanta Juścińska, A. Dobyszuk, A. Krzystyniak, Natalia Marek, J. Myśliwska, A. Hellmann. Clinical Immunology, 2009

696 citations recorded by the source corpus.

Subfields: Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/42ad8d905c90f2ba8511d05a08398edc1bdc0ab9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Miyara
2. David A. Hafler
3. Shimon Sakaguchi
4. D. Hausenloy
5. Alexander Y. Rudensky
6. E. Shevach

Citations in the corpus

• Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities (2018, background): “Preliminary clinical studies have reported ex vivo expanded human TREG cells were safe and effective in the prevention and treatment of graft-versus-host disease or type 1 diabetes mellitus (Brunstein et al., 2011; Marek-Trzonkowska et al., 2014; Trzonkowski et al., 2009).”
• FOXP3+ regulatory T cells in the human immune system (2010, background): “Cellular therapy based on ex vivo expansion of T Reg cells and their transfer to patients is currently the focus of intense research to treat autoimmune disease and inhibit the occurrence of graft-versus-host disease after bone marrow transplantatio”